March 2016

New Product - Flebogamma

Flebogamma 5% DIF (human normal immunoglobulin) is indicated in the following conditions. As replacement therapy in primary immunodeficiency syndromes such as: congenital agammaglobulinaemia and hypogammaglobulinaemia, common variable immunodeficiency, severe combined immunodeficiency and Wiskott Aldrich syndrome; myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; children with congenital AIDS and recurrent infections; immunomodulation; idiopathic thrombocytopenic purpura (ITP), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count; Guillain-Barr√© syndrome; and in allogeneic bone marrow transplantation. It is contraindicated in hypersensitivity to homologous immunoglobulins, especially in very rare cases of IgA deficiency, when the patient has antibodies against IgA, and in fructose intolerance. Flebogamma 5% DIF is supplied as 0.5 g/10 mL, 2.5 g/50 mL, 5 g/100 mL, 10 g/200 mL and 20 g/400 mL single use vials.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia¬†Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au